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Abstract: Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of 
relapses and substantial societal costs. Almost half of the patients are prescribed second genera-
tion antipsychotics for treatment of manic states, or as the maintenance therapy.   Risperidone long 
acting injection (RLAI) as a monotherapy or as adjunctive therapy to lithium or valproate for 
the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration 
(FDA) in United States in May 2009. In this review we will consider the aspects of pharma-
cology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on 
the efficacy of RLAI in bipolar disorder. The patients’ perspective and attitudes to long-acting 
injections will also be discussed.
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Introduction
Bipolar disorder (BD) is a major psychiatric disorder which for years has been under-
diagnosed and – as a consequence – mistreated. The lifetime prevalence figures of 
BD based on studies conducted in 1990s eg, the Epidemiologic Catchment Area1 and 
National Comorbidity Survey2 study were 1.3%–1.6%, respectively. More recent 
data gathered by National Comorbidity Survey-Replication (NCR-R) are based on a 
broader definition of BD spectrum and show that lifetime prevalence estimates are 
4.5% for the BD spectrum, with 1.0% for bipolar I disorder (BP-I), 1.1% for bipolar II 
disorder (BP-II), and 2.4% for subthreshold BPD.3 BPD spectrum was defined as a 
lifetime history of BP-I, BP-II, or subthreshold BPD. Respondents were classified as 
having lifetime BP-I if they had ever had a manic episode; and as having lifetime BP-II 
if they had ever had a hypomanic, but not manic, episode and had ever had a major 
depressive episode (MDE). Definition of subthreshold BPD was based on any of the 
following: 1. recurrent subthreshold hypomania in the presence of intercurrent MDE, 
2. recurrent hypomania in the absence of recurrent MDE, with or without subthreshold 
MDE, and 3. recurrent subthreshold hypomania in the absence of intercurrent MDE 
with, or without subthreshold MDE.
The economic costs of BD are substantial, which is related to a debilitating chro-
nicity and high frequency of relapses in BD. The costs are estimated at $45 billion a 
year in the United States (1991 values), with the economic losses due to work impair-
ment accounting for the largest proportion of this total (nearly $18 billion annually).4 
In comparison the economic costs of major depression from a societal perspective are 
$53 billion a year in the United States (1996 values).5Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Subsequently, the need for the effective maintenance 
therapy of BD could not be overestimated. Although the main 
focus of this review is on the role of risperidone long acting 
injections (RLAI) in maintenance treatment of BD, we will first 
briefly consider existing practices in the use of oral risperidone 
and other second generation antipsychotics (SGA).
National Institute for Health and Clinical Excellence of the 
UK (NICE) guidelines6 recommend starting an antipsychotic, 
valproate or lithium when managing patients in acute manic 
or mixed episode. According to these guidelines, the second 
generation antipsychotics are preferred to first-generation 
antipsychotics. The SGAs currently licensed in the UK for 
the treatment of acute mania are olanzapine, risperidone and 
quetiapine.
A major advantage of the atypical antipsychotics over 
conventional antipsychotics is the lower risk of extrapyrami-
dal symptoms (EPS), though this differential has largely been 
demonstrated in trials where the comparator is haloperidol, 
a high-potency conventional antipsychotic that is associated 
with a relatively high incidence of EPS.
As a long-term maintenance treatment, lithium and olan-
zapine have UK marketing authorization for the prophylaxis 
of bipolar disorder, and carbamazepine has marketing autho-
rization for the prophylaxis of bipolar disorder unresponsive 
to lithium.
In the USA all SGAs (except clozapine) have received the 
FDA indication for BD. Apart from use in acute conditions, 
SGAs appear to be of a broad use at any stage of BD. Thus, 
Sajatovic7 in a report based on the US Veterans health registry, 
demonstrated that 45% (n = 32,994) of patients with BD were 
on antipsychotics as monotherapy or combination therapy. 
The great majority of the   individuals (77.5%, n = 25,559) 
prescribed antipsychotic agents received SGAs.
Current treatment options
Risperidone
The studies show that among other SGAs, oral   risperidone 
may play an important role in long-term treatment of 
bipolar disorder. For example, a large-scale multicenter 
  open-label study involving adjunctive risperidone treatment 
of 541 patients with bipolar disorder or schizoaffective dis-
order8 demonstrated significant, sustained improvements in 
manic and depressive symptoms as well as Clinical Global 
Impression scores. The open, adjunctive nature of risperidone 
use constitutes the major limitation of this study.
There have been concerns about the long-term use 
of risperidone with regard to its potential to induce EPS. 
A naturalistic, retrospective study comparing clozapine, 
risperidone, and olanzapine found no significant difference 
in efficacy or occurrence of EPS among the three groups.9
Another study of risperidone10 looked at both the short-
term and continuation therapy of bipolar mania. This was a 
randomized, double-blind trial of 438 patients, 154 of whom 
were randomized to risperidone, 144 to haloperidol, and 
140 to placebo. After the initial phase of 3 weeks, the patients 
were followed up to another 9 weeks where the effects of 
haloperidol and risperidone were compared. The authors 
report that risperidone monotherapy was an effective and 
well-tolerated treatment for bipolar mania and that efficacy 
was maintained over the long term.
Aripiprazole
Aripiprazole (a partial D2 agonist, 5HT2A antagonist 
and 5HT1A partial agonist) was evaluated in a 100-week 
double-blind, placebo-controlled, relapse prevention study.11 
Efficacy and tolerability of aripiprazole appeared superior 
to placebo in delaying time to manic relapse; however, no 
significant differences were observed in time to depressive 
relapse.
Aripiprazole has also showed good efficacy in a small 
(28 patient) study of patients with rapid-cycling BD which 
demonstrated that aripiprazole was generally well tolerated 
in the long-term treatment (100 weeks) of rapid-cycling 
bipolar disorder.12
Quetiapine
Quetiapine in adjunction with lithium/divalproex has been 
found to be an effective long-term treatment option for bipo-
lar I disorder in preventing recurrences not only of mania 
but also depression; for example Vieta at al13 examined 
the efficacy and safety of quetiapine in combination with 
lithium or divalproex as compared with placebo and lithium 
or divalproex, and found that treatment with quetiapine in 
combination with lithium/divalproex significantly increased 
time to recurrence of any event (mania, depression, or mixed) 
irrespective of the polarity of the index episode compared 
with placebo. Long-term treatment with quetiapine was 
generally well tolerated.
In another trial,14 after the 12 week period of open-label 
stabilization, 628 patients were randomly assigned to double-
blind treatment with quetiapine or placebo, in combination with 
lithium or divalproex, for up to 104 weeks. The primary efficacy 
measure was time to recurrence of any mood event (mania, 
depression, or a mixed episode). The results showed that fewer 
patients in the quetiapine group experienced a mood event 
compared with the placebo group (20.3% versus 52.1%).Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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The beneficial effect of quetiapine in relapse prevention 
was demonstrated in a small (21-patient) adolescent sample 
as well.15
Seroquel XR (quetiapine fumarate) Extended-Release 
Tablets were approved in 2008 by the FDA for the mainte-
nance treatment of BP-I as an adjunct therapy to lithium or 
divalproex. It also has FDA approval as monotherapy for 
treatment for bipolar disorder-acute depressive episodes, and 
bipolar I disorder-acute manic or mixed episodes.
Olanzapine
Olanzapine has been used most widely for the long-term 
treatment of BD and there is a large amount of data on its 
efficacy and tolerability. The recent Cochrane review16 evalu-
ated the effects of olanzapine as a monotherapy or adjunc-
tive treatment in preventing manic, depressive, and mixed 
episodes in patients with bipolar affective disorder, based 
on 5 trials with 1165 participants.
The analysis showed that there was no statistically sig-
nificant difference between olanzapine and placebo (either 
alone or in combination with lithium or valproate) in terms 
of number of participants who experienced relapse into 
mood episode; however restricting the analysis to the trial 
that compared olanzapine monotherapy versus placebo, 
there was a statistically significant difference in favor of 
olanzapine. No statistically significant difference was found 
between olanzapine and other mood stabilizers (lithium or 
valproate) in preventing symptomatic relapse for any mood 
episode, however, olanzapine was more effective than lithium 
in preventing symptomatic manic relapse. As a downside, 
olanzapine either alone or as adjunctive treatment to mood 
stabilizers was associated with significantly greater weight 
gain than placebo. Although olanzapine was associated with 
a lower rate of manic relapse, there was evidence for higher 
rate of weight increase and depression associated with olan-
zapine than lithium. The authors concluded that the evidence 
is in favor of lithium as the first line maintenance treatment 
of bipolar disorder.
Monotherapy versus combined 
therapy
The decision – which medication to choose for the maintenance 
treatment and whether or not administer it as a monotherapy or 
combined with antimanic medication – is not a trivial one. This 
is particularly important when considering the maintenance 
treatment with a long-acting medication, eg, RLAI.
First, it is essential to consider that the profiles of respond-
ers to lithium, valproate and SGAs are different. The author 
of a thoughtful review17 gives examples where, for example, 
manic patients who had previously responded well to lithium 
later responded well to lithium again, but not to divalproex. 
Similarly, it has been reported that olanzapine treatment 
succeeded in patients who had previously failed on lithium 
and divalproex treatment. The author concludes that these 
“observations of selective response do not support the clini-
cal impression that many bipolar patients benefit partially 
from several different treatments and that, therefore, these 
treatments usually need to be combined”. Subsequently, 
because monotherapies can often be helpful in carefully 
selected bipolar patients, the author recommends the use of 
combinations in more specific situations – for example, when 
a patient fails on adequate monotherapy, when clinical data 
provide no leads as to which monotherapy to choose (such 
as in an early episode), or when a patient does not tolerate 
adequate monotherapy.
Compliance problems
One of the problems encountered by the prescribers of long-
term treatment of BD is the patients’ poor compliance with 
the medication.
The factors associated with medication compliance could 
be grouped to those related to patient’s personality, effects of 
illness, or effects of the medication. A recent study18 noted 
that the range of treatment non-adherence in patients with BD 
varies from 20%–70% in different studies. The results of that 
study showed that 12% were largely nonadherent to long-term 
treatment. The authors concluded that non-adherent patients 
with bipolar disorder received less intensive pharmaco-
logic treatments, had more suicide attempts, and experienced 
more barriers to care than adherent individuals.
There have been indications that the treatment   adherence 
depends on the type of medication. For example, the study19 
showed that the patients treated with quetiapine had signifi-
cantly greater regularity of prescription refills than individuals 
treated with typical antipsychotics, risperidone, or olanzapine. 
Quetiapine and risperidone were associated with a longer 
treatment duration than the typical antipsychotics, olanzapine, 
or ziprasidone. The authors suggest that the clinicians should 
aim at achieving the optimum balance between efficacy and 
adverse effects.
In some non-compliant patients with bipolar disorder who 
would benefit from a long-term antipsychotic, a long-acting 
injection (LAI) may aid compliance. Although not specifi-
cally addressing BD, a recent editorial20 provides very useful 
overview of advantages of the LAI over the oral formulations 
and vice versa. For example, easier and early detection of Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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relapse, relapse prevention, and reduced re-hospitalization 
rates could count as the definite advantages of LAI, whereas 
the oral formulations may prove advantageous with regard 
to the possibility of rapid discontinuation in cases of serious 
side effects, providing patients with an enhanced sense of 
autonomy and reducing stigma.
There are only two SGAs available as the long-acting 
injections: olanzapine pamoate and risperidone long acting 
injections (RLAI).
Olanzapine pamoate is licensed in the UK for long-
term treatment of schizophrenia, but there have been safety 
concerns due to post-injection delirium/sedation syndrome 
(PDSS).21 This requires a risk management plan that includes 
supervision of the patient by health care personnel for 3 hours 
post-injection. To date there have been no published articles 
on use of this preparation in BD.
The use of risperidone long-acting 
injections
Introduction to the compound
The active component of RLAI – risperidone – is a benzisox-
azole derivative with potent combined serotonin 5HT2A 
and dopamine D2 receptor-blocking properties. Adrenergic 
α1 and to a lesser extent, histamine H1 and adrenergic 
α2 receptors are also antagonized by risperidone.
To date there have been several studies, and one review 
article,22 addressing the role of RLAI in the maintenance 
treatment of BD.
RLAI as monotherapy, or as adjunctive therapy to 
lithium or valproate, for the maintenance treatment of BP-I 
was approved by FDA in United States in May 2009. The 
recommended dose for monotherapy, or adjunctive therapy 
to lithium or valproate, for the maintenance treatment of BP-I 
is 25 mg IM every 2 weeks. Some patients may benefit from 
a higher dose of 37.5 mg or 50 mg. Dosages above 50 mg 
have not been studied in this population.
In the UK long-acting intramuscular injections of antip-
sychotics (‘depots’) are not recommended for routine use in 
bipolar disorder. NICE recommends though that they may 
be considered for people who were treated successfully 
for mania with oral antipsychotics, but have had a relapse 
because of poor adherence.
Pharmacology, pharmacokinetics 
and neuroimaging data on RLAI
Typical antipsychotic depot preparations are delivered in 
an oil-based suspension, with a high level of side-effects 
related to the oil-based medium in which the medication 
is suspended. Particularly, this can lead to the development 
of nodules at the injection site over time. RLAI is a water-
based suspension that contains the active drug in glycolic 
acid–lactate microspheres. As the parent compound risperi-
done lacks the hydroxyl group traditionally used to bind to 
an ester to facilitate the production of a slow-release mecha-
nism, a delivery system of glycolic acid–lactate copolymer 
microspheres containing the drug was developed. Following 
injection, the microspheres are progressively hydrolyzed, 
leading to a slow and steady release of risperidone over a 
period of several weeks. The majority of the release occurs 
during weeks 4–6 after the injection. Therefore the patients 
should be maintained on oral risperidone for the first three 
weeks of initiation of RLAI.
The pharmacokinetic profile of RLAI exhibits less peak-
to-trough variability than that of oral risperidone, and lower 
peak plasma concentrations, as a result of the delayed release 
of active agent from the vehicle microspheres.23 After injec-
tion, less than 1% of the administered dose is released ini-
tially; the main release of risperidone occurs after a period of 
3 weeks. Release is sustained during weeks 4 to 6 and begins 
to subside by week 7. The elimination phase is complete at 
7 to 8 weeks following microsphere breakdown. Repeated 
administration of RLAI every 2 weeks achieves steady-state 
plasma levels after the fourth injection. Therefore, the use 
of RLAI ensures continuous antipsychotic coverage.24 The 
pharmacokinetics of RLAI are linear in the usual dose range 
of 25 to 50 mg.
Oral risperidone undergoes significant ‘first-pass’ 
metabolism – 90% is bound in plasma to albumin and alpha-1 
acid glycoprotein prior to elimination via the kidneys. Plasma 
levels are normal in patients with hepatic insufficiency, but 
may be raised by 60% in patients with renal impairment. The 
advantages of RLAI formulation include the avoidance of 
first-pass metabolism, attenuated fluctuations between peak 
and trough concentrations, and the certainty of medication 
delivery. Eerdekens et al24 evaluated the pharmacokinetics 
and tolerability of RLAI in a multicenter, prospective, open-
label, 15-week study of 86 patients with schizophrenia. They 
found that the mean steady-state peak concentrations of the 
active moiety were significantly lower with intramuscular 
than oral dosing, and fluctuations in plasma active-moiety 
levels were significantly lower with the RLAI than oral 
risperidone.
Nesvåg et al25 showed that the patients receiving RLAI 
had lower mean concentration of risperidone plus 9-OH-
risperidone, and a lower 9-OH-risperidone/risperidone ratio Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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than patients taking oral risperidone. The difference in mean 
total serum concentration was mainly due to lower mean 
  concentration of 9-OH-risperidone in the group receiving 
RLAI, while the mean concentration of risperidone was 
equal in the two groups. The lower level of 9-OH-risperi-
done in the RLAI group may represent reduced first-pass 
metabolism.
The pharmacological activity of risperidone and 
9-OH-risperidone is claimed to be similar, but no direct 
evidence for this has been reported. It has been proposed 
that the drug’s therapeutic activity is mediated through a 
combination of dopamine Type 2 (D2) and serotonin Type 2 
(5HT2) receptor antagonism.
Positron emission tomography studies have shown 
a central dopamine receptor occupancy of 70% to 
be associated with clinical efficacy for typical oral 
antipsychotic agents. A D2-occupancy of 53%–85% 
was found in seven patients treated with a daily dose of 
3–6 mg of oral risperidone.26 Another positron emission 
tomography study showed a D2-occupancy of 25%–72% 
in eight patients after receiving three or five injections of 
25–75 mg RLAI.27
Functional magnetic resonance (fMRI) studies of pat-
ents with schizophrenia demonstrated that treatment with 
RLAI – as compared with the first generation depot antip-
sychotics – was associated with a normalisation of blood 
oxygenation level dependent (BOLD) response in the medial 
prefrontal cortex in tasks involving working memory28 and 
facial emotion processing.29
Following subcutaneous injections of risperidone, 
9-OH-risperidone was found to have a limited distribution 
compared with risperidone in frontal and striatal regions in 
the rat brain.30 These differences in distribution of risperi-
done and 9-OH-risperidone in the rat brain indicate that the 
parent drug and metabolite may have different pharmacoki-
netic properties which may be relevant to the antipsychotic 
efficacy of the agent.31 Intramuscular injections of depot 
antipsychotic agents imply a more stable serum drug level 
and improved compliance compared with oral medication.32 
Thus a lower mean serum drug level prior to next injection 
may not necessarily imply lower antipsychotic efficacy 
throughout the time span between injections. However, 
among patients receiving oral risperidone there is only a 
weak association between serum drug levels and clinical 
response and adverse effects.33 This is also the case for typi-
cal depot agents. Therefore, possible clinical implications 
of a difference in serum drug levels between oral and RLAI 
remain obscure.
Administration
Thyssen et al34 reported the results of two studies in chronic 
schizophrenic individuals where RLAI was administered into 
the deltoid versus gluteal muscle. The first study included 
a large sample of 170 patients in a multicenter, open-label, 
single-dose, 2-way, cross-over design. During each treatment 
period, patients received a single injection into the deltoid or 
gluteal muscle on day 1 followed by an 85-day observation/
washout period. In the second study, they reported the safety 
and tolerability of RLAI administered into the deltoid. This 
was an 8-week open-label, multicenter, multidose study with 
53 patients who required higher doses and who had previ-
ously received RLAI gluteal injections. During the 8-week 
treatment phase, patients received 4 sequential intramuscular 
injections of RLAI 37.5 mg or 50 mg, administered every 
2 weeks into the deltoid muscle. In both studies, RLAI doses 
were administered with 2 mL of diluent as an intramuscular 
injection. The 2 mL diluent volume was considered as an 
acceptable volume for deltoid injections of aqueous fluids, 
and is the approved marketed volume for gluteal injections 
of RLAI . This multidose study was designed to evaluate the 
discontinuation rate of schizophrenic subjects   receiving mul-
tiple biweekly deltoid injections of 37.5 or 50 mg of RLAI. 
This study had an 83% completion rate. In both studies, no 
patient withdrew due to injection-site tolerability issues.
In the single-dose study, there was slightly higher inci-
dence of injection site reactions following deltoid injection 
compared with gluteal injection. However, these reactions 
were mild and did not appear to be clinically significant. 
Furthermore, none of the subjects who discontinued did so 
because of reasons related to the injection site. Investiga-
tors rated the injection site reactions which did not reveal 
any nodule formations. In the majority of patients, post-
administration pain was rated as either minimal or none in 
the first 24 hours following injection.
The shape of the plasma concentration-time profiles 
following single deltoid and gluteal injection were similar. 
The shape of plasma concentration-time curves of the active 
moiety, risperidone, and 9-OH-risperidone were similar in the 
different treatment groups. Peak active moiety plasma con-
centrations were achieved after approximately 30 days for all 
treatments, with an apparent elimination half-life of 6 to 8 days, 
independent of dose or injection site. Bioequivalence was 
demonstrated irrespective of the pre-dose concentration of 
the active moiety. The plasma exposure increased with dose, 
and dose-proportionality was shown after deltoid injection of 
37.5 mg and 50 mg of RLAI and after gluteal injection of 25 mg 
and 50 mg of RLAI. Cross-panel and cross-study graphical Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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comparison for the different deltoid and gluteal treatments 
showed that dose-normalized pharmacokinetic parameters 
were similar across treatments (ie, doses and injection sites).
Thus, based on the pharmacokinetic results, the authors 
concluded that RLAI injection was safe and well tolerated 
when administered as a single gluteal injection or as a single 
deltoid injection or multiple deltoid injections. The injection 
of RLAI into the deltoid muscle can offer patients a more 
acceptable and convenient route of administration that may 
enhance overall long-term treatment adherence.
Safety and tolerability issues
Malempati et al35 found that the RLAI was well tolerated in 
all patients with bipolar disorder. EPS were present in 30% 
of the bipolar patients and were reduced compared with prior 
medication therapy in 30% of the patients. Only one patient 
required concomitant treatment with an anticholinergic 
medication. The average weight gain over 2 years was low 
(1.6 kg) and other side effects were minimal.
The studies below report on various side effects of RLAI 
treatment in mixed groups of patients. Han et al36 found no 
significant body weight change in their study during RLAI 
treatment, although 4 participants switched to RLAI due to 
weight gain. On the other hand, Mohl et al37 reported a small 
but significant body weight shift in their study using RLAI 
in stable patients with schizoaffective disorder.
In a retrospective study, Camacho et al38 enrolled 
50 patients suffering from schizophrenia or bipolar disorder 
with a history of poor medication adherence. The results 
revealed generally high patient adherence with such a pro-
gram and meaningful improvements in attendance to their 
appointments as well as global functioning. In terms of their 
weight, it was noted that patients receiving RLAI for at least 
one year had 3% increase of their mean weight. These results 
are only observational since patients were receiving other 
psychotropic drugs in addition to the RLAI.
In the study of Niaz and Haddad,39 the sample comprised 
90 patients with schizophrenia, schizoaffective, or bipolar 
affective disorder. No adverse effects of RLAI treatment were 
present in one third of the patients. One third had no record 
of the presence or absence of adverse effects, and the last 
one third recorded an adverse effect attributed to RLAI. The 
most common adverse effect was a movement disorder (EPS 
including akathisia), but also a raised prolactin, increased 
sedation, sexual dysfunction, hypersalivation, weight gain, 
painful injection, anxiety and sleep disturbance. In this 
sample, half of the 90 patients who commenced RLAI had 
stopped it by the evaluation point. Lack of efficacy accounted 
for approximately 40% and intolerability for approximately 
20%. Despite these results, this study showed that RLAI was 
associated with a reduction in total admissions, compulsory 
admissions, and total inpatient days and was cost-effective.
When reviewing the results of side effects of various LAI 
across different studies, Taylor40 pointed to huge inconsisten-
cies in dosage, with the likelihood that LAI-treated patients 
may often be significantly overdosed. This consideration 
should be taken into account when evaluating the side effects 
of RLAI as well.
Use of RLAI as monotherapy 
and as an adjuvant to lithium or 
valproate
Only a small number of studies have been published on 
the use of RLAI in bipolar disorder. The patient samples in 
some studies have been mixed – eg, comprising individuals 
with bipolar disorder and schizophrenia or schizoaffective 
disorder.
In an open label observational study with RLAI,41 
14 patients met the diagnostic criteria of BP-I and 8 patients 
met the diagnostic criteria of schizophrenia according to 
the DSM-IV-TR. These patients were characterized by the 
treatment non-compliance and frequent relapses that led to 
the subsequent hospitalization. The maintenance treatment 
was followed up to 40 weeks during which no depressive 
symptoms or significant adverse effects were observed.
Ten outpatients with BP-I or BP-II were prescribed open-
label RLAI 25–50 mg every 2 weeks as an adjunct to ongoing 
treatment with mood stabilizing and other medications.35 
Depressive episodes predominated over manic/hypomanic/
mixed episodes in all patients prior to initiation of treatment 
with RLAI. During the 2-year follow-up period, manic 
symptoms declined over time in all patients and depressive 
symptoms were minimal. No patients required hospitalization 
for mood episodes. One patient suffered a manic episode, 
one experienced hypomania, and two had mixed episodes. 
All mood elevations were relatively mild and all patients 
demonstrated improvement in psychosocial functioning dur-
ing the follow-up period. The authors concluded that RLAI 
may be useful in poorly compliant bipolar patients at high 
risk of manic relapse.
On a small sample of 11 bipolar patients,36 the authors 
showed that RLAI may be beneficial in the maintenance 
therapy of stable bipolar patients. In this exploratory trial, 
the maintenance of a euthymic mood state was achieved 
during the 12 months of treatment, with low Young Mania 
Rating Scale (YMRS) scores that could be regarded to indi-Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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cate remission. Moreover, the patients and the caregivers 
reported high levels of satisfaction. The treatment was well 
tolerated and showed advantages in achieving compliance. 
The authors recommend the use of small doses of RLAI 
(25 mg), which would be a positive aspect for long-term 
successful management of BP-I.
Yatham et al42 prospectively assessed the safety and 
  efficacy of RLAI in comparison to oral atypical antipsychot-
ics (risperidone, quetiapine, or olanzapine) in the longer term 
treatment of bipolar disorder, using a 6-month, open-label, 
randomized design. The 49 bipolar outpatients who were 
treated with a mood stabilizer and an oral second-generation 
antipsychotic at baseline were randomized to either con-
tinue their respective antipsychotic regimen or to switch to 
RLAI.
In RLAI patients, and those on oral atypical antipsychotic 
patients, there were similar rates of at least one treatment-
related adverse event (70% and 73%, respectively). Most 
frequently reported adverse events for RLAI were insom-
nia, nausea, fatigue and headache. Also in this study, RLAI 
was commenced at 25 mg for a minimum of 6 weeks, with 
stringent recommendations regarding dose increases. Each 
subsequent RLAI dose increase was maintained for a mini-
mum of 4 weeks before permitting a final dose increase. The 
authors argued that this limitation may have biased the results 
in favor of oral atypical antipsychotic. Still, this study showed 
that RLAI has similar efficacy and tolerability in comparison 
to oral atypical antipsychotics.
A 6-month case series of 12 bipolar patients43 reported 
a response rate of 100% by endpoint, with no depressive 
episodes in any patients. RLAI was well tolerated, somatic 
complaints were limited, with 8% reporting dizziness and 
16% reporting constipation. No significant adverse events 
(including EPS) occurred. RLAI significantly reduced the 
severity of symptoms, and no manic or depressive episodes 
were seen in these previously noncompliant patients in 
6-month period. Also, switching from mood stabilizers, or 
mood stabilizers plus atypical antipsychotics, to RLAI, or 
adding on RLAI, was safe and well tolerated in our popula-
tion. These naturalistic, uncontrolled observations suggest 
the potential of RLAI in the long-term management of BP-I 
patients.
In the first prospective study to assess the effectiveness 
of RLAI in a cohort of bipolar patients, Vieta et al44 entered 
29 acutely manic bipolar inpatients in a mirror-design, 
observational study. They received naturalistic treatment 
for a manic episode plus RLAI for a mean period of 2 years. 
Side effects were reported by nine patients. Five of them 
reported EPS and needed antiparkinsonian medication. Three 
patients had prolactin level elevation and one complained 
of impotence. Another patient reported depression as a side 
effect. Only four subjects stopped the treatment due to the 
side effects. Weight gain occurred in five patients (17%). 
Weight gain was found to be similar to the weight gained 
during oral risperidone therapy.
The only double-blind, randomized trial published to 
date was supported by Ortho-McNeil Janssen Scientific 
Affairs.45 This study included patients with BD-I with four 
and more mood episodes in the 12 months prior to study 
entry. Following a 16-week, open-label stabilization phase 
with RLAI plus treatment as usual (TAU), remitted patients 
entered a 52-week, double-blind, placebo-controlled, relapse-
prevention phase. Randomized patients continued treatment 
with adjunctive RLAI (25–50 mg every 2 weeks) plus TAU 
(n = 65) or switched to adjunctive placebo injection plus 
TAU (n = 59). The primary outcome measure was time to 
relapse to any mood episode. Out of 240 enrolled patients, 
124 entered double-blind treatment. Time to relapse was 
longer in patients receiving adjunctive RLAI (P = 0.010). 
Relative relapse risk was 2.3-fold higher with adjunctive 
placebo (P = 0.011). Side effect profile was more benign 
in adjunctive RLAI group compared with that in adjunctive 
placebo one. The authors concluded that adjunctive RLAI 
significantly delayed time to relapse in patients with BP-I 
who relapse frequently.
Efficacy studies in elderly patients
Bipolar disorder in older adult populations has gained 
increasing attention due to the growing proportion of elderly, 
eg, in the US it is predicted to increase from about 4 million 
in 1970 to 15 million in 2030.46
A study of Hirshfeld et al47 reported the prevalence of 
bipolar disorder at 0.5% among individuals aged 65 and 
older as bipolar illness persists into later life.
A continuing unmet need is the identification of agents 
that are generally well tolerated and effective in later-life 
bipolar disorder. Medications that are first-line treatments in 
younger patients, such as lithium, may be poorly tolerated 
in older patients due to side effects and renal dysfunction. 
Additional strategies for treatment of bipolar disorder in 
late-life are needed.
No data is available concerning the efficacy of RLAI in 
elderly patients with BD.
The choice of an antipsychotic medication should be based 
on patients’ history of response and personal preference, clini-
cian’s previous experience, and pharmacokinetic properties.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
462
El-Hage and Surguladze
Caution is required in older patients with renal or hepatic 
impairment, and in subjects with decreased rates of renal 
blood flow, glomerular filtration, and renal clearance, as 
well as reduced levels of synthesis and activity of hepatic 
microsomal enzymes. An age-related fall in total body water 
results in higher plasma concentrations which may increase 
both activity and the potential for adverse effects of RLAI 
as water-based compound.48
A report of RLAI treatment of 52 elderly patients 
(65 years and older) with schizophrenia, schizoaffective, 
and other psychotic disorders may serve as an approximate 
guide.49 The patients were switched from stable antipsy-
chotic regimens. The most common dosage of RLAI used 
at endpoint was 25 mg every 14 days. Conversion to RLAI 
resulted in significant improvements in movement disorder 
severity,   psychiatric symptoms, functional status. and patient 
satisfaction. In general, the results showed that RLAI was 
well tolerated and safe in elderly patients with psychotic 
illnesses.
Patient-focused perspectives such 
as quality of life, patient satisfaction, 
acceptability, adherence and uptake
There is little data available regarding long-term use of 
RLAI in patients with BD. The question remains to be 
answered – will the patients stay on this medication once 
stabilized? We can only provide an example from the study 
of schizophrenia patients50 where the investigators found 
that out of 211 patients, over 3 years, 84% of subjects dis-
continued RLAI; 27.7% of these switched to oral risperi-
done. Amongst the factors predicting greater probability 
of discontinuation were younger age, longer duration of 
illness, inpatient status at initiation, and an RLAI dose of 
25 mg/2 weeks.
The cross-sectional study51 sheds light on other factors 
that could be relevant for RLAI treatment in BD. In par-
ticular, these authors evaluated perceived treatment effects, 
patients concerns, and expectations among 90 individuals 
with BD. The study showed that while individuals with BD 
appreciated the effects of medications on keeping them 
stable, their concerns regarding adverse effects were not 
insignificant. Another aspect, relevant for long-term treat-
ment, was the perceived discrepancy between actual and 
hoped-for outcome.
Thus, the question arises – what is it that the clinician is 
offering to patient “in exchange” to regular visits to the depot 
clinic? Is it a better quality of life? This latter aspect deserves 
further investigation.
Conclusion
The efficacy of RLAI in maintenance treatment of BD has been 
evaluated in a small number of studies, with one published 
report of a double-blind, randomized controlled trial thus far.45 
Much has to be done in terms of establishing the true value of 
this preparation in the long-term management of BD.
The studies published to date converge on highlight-
ing the positive effects of RLAI in terms of improving 
adherence, reducing the relapse rates, and overall good 
tolerability.
Still, there are more questions to be answered regarding 
the place that RLAI might have in the long-term therapy of 
BD. In particular how cost-effective is the long-term use of 
RLAI? Do the patients need the RLAI at all in adjunction to 
the well established antimanic agents ie, lithium, valproate or 
carbamazepine? Why don’t we aim for monotherapy? And, 
if we do, could RLAI prove effective as a monotherapy in 
maintenance treatment of BD? How can we justify the long-
term use of injectable antipsychotic to BD patients – eg, when 
they are in remission? Shall we tell them that BD is a kind 
of chronic psychosis?
A recent editorial in The British Journal of Psychiatry 
dedicated to the role of LAI in the treatment of schizophrenia52 
emphasized that it was a “very real issue that most people are 
uncomfortable about the prospect of taking long-acting drugs – 
particularly drugs that can profoundly change how one feels, 
with no way of reversing these effects for several weeks”. This 
might be particularly true in the case of BD where patients feel 
“back to normal” after recovering from the mood episode.
More studies directly addressing these questions are war-
ranted, as well as a broader discussion related to the patient’s 
perspective with regard to long-term injectable antipsychotics 
in general.
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